Research and Markets (http://www.researchandmarkets.com/research/bfpxf4/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Gastrointestinal Stromal Tumor (GIST) Overview
- Therapeutics Development
- Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview
- Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis
- Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies
- Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes
- Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies
- Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes
- Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development
For more information visit http://www.researchandmarkets.com/research/bfpxf4/gastrointestinal
View source version on businesswire.com: http://www.businesswire.com/news/home/20160122005615/en/